Skip to main content
Erschienen in: World Journal of Urology 2/2005

01.07.2005 | Free Paper

Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms—a placebo-controlled, double-blind, multicenter trial

verfasst von: N. Lopatkin, A. Sivkov, C. Walther, S. Schläfke, A. Medvedev, J. Avdeichuk, G. Golubev, K. Melnik, N. Elenberger, U. Engelmann

Erschienen in: World Journal of Urology | Ausgabe 2/2005

Einloggen, um Zugang zu erhalten

Abstract

The efficacy and tolerability of a fixed combination of 160 mg sabal fruit extract WS 1473 and 120 mg urtica root extract WS 1031 per capsule (PRO 160/120) was investigated in elderly, male patients suffering from lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia in a prospective multicenter trial. A total of 257 patients (129 and 128, respectively) were randomized to treatment with PRO 160/120 or placebo (127 and 126 were evaluable for efficacy). Following a single-blind placebo run-in phase of 2 weeks, the patients received 2×1 capsule/day of the study medication under double-blind conditions over a period of 24 weeks. Double-blind treatment was followed by an open control period of 24 weeks during which all patients were administered PRO 160/120. Outcome measures for treatment efficacy included the assessment of the patients’ LUTS by means of the I-PSS self-rating questionnaire and a quality of life index as well as uroflow and sonographic parameters. Using the International Prostate Symptom Score (I-PSS), patients treated with PRO 160/120 exhibited a substantially higher total score reduction after 24 weeks of double-blind treatment than patients of the placebo group (6 points vs 4 points; P=0.003, one tailed) with a tendency in the same direction after 16 weeks. This applied to obstructive as well as to irritative symptoms, and to patients with moderate or severe symptoms at baseline. Patients randomized to placebo showed a marked improvement in LUTS (as measured by the I-PSS) after being switched to PRO 160/120 during the control period (P=0.01, one tailed, in comparison to those who had been treated with PRO 160/120 in the double-blind phase). The tolerability of PRO 160/120 was comparable to the placebo. In conclusion, PRO 160/120 was clearly superior to the placebo for the amelioration of LUTS as measured by the I-PSS. PRO 160/120 is advantageous in obstructive and irritative urinary symptoms and in patients with moderate and severe symptoms. The tolerability of the herbal extract was excellent.
Literatur
1.
Zurück zum Zitat Alken CE (1973) Leitfaden der Urologie. Thieme, Stuttgart, pp 180–182 Alken CE (1973) Leitfaden der Urologie. Thieme, Stuttgart, pp 180–182
2.
Zurück zum Zitat Aso Y, Abbou C, Abrams P et al. (1996) Clinical research criteria. In: Cockett ATC et al. (eds) Third International Consultation on BPH. Monaco, 26–28 June 1995, Proceedings. Scientific Communication International, Channel Islands, pp 453–466 Aso Y, Abbou C, Abrams P et al. (1996) Clinical research criteria. In: Cockett ATC et al. (eds) Third International Consultation on BPH. Monaco, 26–28 June 1995, Proceedings. Scientific Communication International, Channel Islands, pp 453–466
3.
Zurück zum Zitat Bach D (2000) Placebokontrollierte Langzeittherapiestudie mit Kürbissamenextrakt bei BPH-bedingten Miktionsbeschwerden. Interdisziplinärer Arbeitskreis Prostata. Urologe B 40:437–443CrossRef Bach D (2000) Placebokontrollierte Langzeittherapiestudie mit Kürbissamenextrakt bei BPH-bedingten Miktionsbeschwerden. Interdisziplinärer Arbeitskreis Prostata. Urologe B 40:437–443CrossRef
4.
Zurück zum Zitat Berges RR, Pientka L, Höfner K, Senge T, Jonas U (2001) Male lower urinary tract symptoms and related health care seeking in Germany. Eur Urol 39:682–687 Berges RR, Pientka L, Höfner K, Senge T, Jonas U (2001) Male lower urinary tract symptoms and related health care seeking in Germany. Eur Urol 39:682–687
5.
Zurück zum Zitat Cockett ATK, Khoury S, Aso Y, Chatelain C Denis L, Griffiths K, Murphy G (eds) (1994) The 2nd International Consultation on Benign Prostatic Hyperplasia (BPH). Paris, 27–30 June 1993 Cockett ATK, Khoury S, Aso Y, Chatelain C Denis L, Griffiths K, Murphy G (eds) (1994) The 2nd International Consultation on Benign Prostatic Hyperplasia (BPH). Paris, 27–30 June 1993
6.
Zurück zum Zitat Dathe G, Schmid H (1987) Phytotherapie der benignen Prostatahyperplasie (BPH). Doppelblindstudie mit Extractum Radicis urticae (ERU). Urologe B 27:223–226 Dathe G, Schmid H (1987) Phytotherapie der benignen Prostatahyperplasie (BPH). Doppelblindstudie mit Extractum Radicis urticae (ERU). Urologe B 27:223–226
7.
Zurück zum Zitat Djavan B, Marberger M (1999) A meta-analysis on the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 36:1–13 Djavan B, Marberger M (1999) A meta-analysis on the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 36:1–13
8.
Zurück zum Zitat Düker E-M, Kopanski L, Schweikert HU (1989) Inhibition of 5α-reductase activity by extracts from Sabal serrulata. Planta Med 55:587 Düker E-M, Kopanski L, Schweikert HU (1989) Inhibition of 5α-reductase activity by extracts from Sabal serrulata. Planta Med 55:587
9.
Zurück zum Zitat Gabrič V, Miskič H (1987) Behandlung des benignen Prostataadenoms und der chronischen Prostatitis. Placebokontrollierte randomisierte Doppelblindstudie mit Prostagutt®. Therapiewoche 37:1775–1788 Gabrič V, Miskič H (1987) Behandlung des benignen Prostataadenoms und der chronischen Prostatitis. Placebokontrollierte randomisierte Doppelblindstudie mit Prostagutt®. Therapiewoche 37:1775–1788
10.
Zurück zum Zitat Goepel M, Hecker U, Krege S, Rübben H, Michel MC (1999) Saw palmetto extracts potently and noncompetitively inhibit human α1-adrenoceptors in vitro. Prostate 38:208–215CrossRefPubMed Goepel M, Hecker U, Krege S, Rübben H, Michel MC (1999) Saw palmetto extracts potently and noncompetitively inhibit human α1-adrenoceptors in vitro. Prostate 38:208–215CrossRefPubMed
11.
Zurück zum Zitat Golomb J, Lindner A, Siegel Y, Korczak D (1992) Variability and circadian changes in home uroflowmetry in patients with benign prostatic hyperplasia compared to normal controls. J Urol 147:1044–1047PubMed Golomb J, Lindner A, Siegel Y, Korczak D (1992) Variability and circadian changes in home uroflowmetry in patients with benign prostatic hyperplasia compared to normal controls. J Urol 147:1044–1047PubMed
12.
Zurück zum Zitat Hansen BJ, Meyhoff HH, Nordling J, Mensink HJ, Mogensen P, Larsen EH (1996) Placebo effects in the pharmacological treatment of uncomplicated benign prostatic hyperplasia. The ALFECH Study Group. Scand J Urol Nephrol 30:373–377PubMed Hansen BJ, Meyhoff HH, Nordling J, Mensink HJ, Mogensen P, Larsen EH (1996) Placebo effects in the pharmacological treatment of uncomplicated benign prostatic hyperplasia. The ALFECH Study Group. Scand J Urol Nephrol 30:373–377PubMed
13.
Zurück zum Zitat Hirano T, Homma M, Oka K (1994) Effects of stinging nettle root extracts and their steroidal components on the Na+,K+-ATPase of the benign prostatic hyperplasia. Planta Med 60:30–33 Hirano T, Homma M, Oka K (1994) Effects of stinging nettle root extracts and their steroidal components on the Na+,K+-ATPase of the benign prostatic hyperplasia. Planta Med 60:30–33
14.
Zurück zum Zitat Isaacs JT, Brendler CB, Walsh PC (1983) Changes in the metabolism of dihydrotestosterone in the hyperplastic human prostate. J Clin Endocrinol Metab 56:139–146 Isaacs JT, Brendler CB, Walsh PC (1983) Changes in the metabolism of dihydrotestosterone in the hyperplastic human prostate. J Clin Endocrinol Metab 56:139–146
15.
Zurück zum Zitat Koch E (2001) Extracts from fruits of saw palmetto (Sabal serrulata) and roots of stinging nettle (Urtica dioica): viable alternatives in the medical treatment of benign prostatic hyperplasia and associated lower urinary tracts symptoms. Planta Med 67:489–500CrossRefPubMed Koch E (2001) Extracts from fruits of saw palmetto (Sabal serrulata) and roots of stinging nettle (Urtica dioica): viable alternatives in the medical treatment of benign prostatic hyperplasia and associated lower urinary tracts symptoms. Planta Med 67:489–500CrossRefPubMed
16.
Zurück zum Zitat Koch E, Biber A (1994) Pharmakologische Wirkungen von Sabal- und Urtikaextrakten als Grundlage für eine rationale medikamentöse Therapie der benignen Prostatahyperplasie. Urologe B 34:95–100 Koch E, Biber A (1994) Pharmakologische Wirkungen von Sabal- und Urtikaextrakten als Grundlage für eine rationale medikamentöse Therapie der benignen Prostatahyperplasie. Urologe B 34:95–100
17.
Zurück zum Zitat Lichius JJ, Lenz C, Lindemann P, Müller H-H, Aumüller G, Konrad L (1999) Antiproliferative effect of a polysaccharide fraction of a 20% methanolic extract of stinging nettle roots upon epithelial cells of the human prostate (LNCaP). Pharmazie 54:768–771PubMed Lichius JJ, Lenz C, Lindemann P, Müller H-H, Aumüller G, Konrad L (1999) Antiproliferative effect of a polysaccharide fraction of a 20% methanolic extract of stinging nettle roots upon epithelial cells of the human prostate (LNCaP). Pharmazie 54:768–771PubMed
18.
Zurück zum Zitat Maurer W, Hothorn LA, Lehmacher W (1995) Multiple comparisons in drug clinical trials and preclinical assays: a-priori ordered hypotheses. In: Vollmar J (ed) Testprinzipien in klinischen und präklinischen Studien. Biometrie in der chemisch-pharmazeutischen Industrie, vol 6. Gustav Fischer, Stuttgart, pp 3–18 Maurer W, Hothorn LA, Lehmacher W (1995) Multiple comparisons in drug clinical trials and preclinical assays: a-priori ordered hypotheses. In: Vollmar J (ed) Testprinzipien in klinischen und präklinischen Studien. Biometrie in der chemisch-pharmazeutischen Industrie, vol 6. Gustav Fischer, Stuttgart, pp 3–18
19.
Zurück zum Zitat McConnell JD, Bruskewitz R, Walsh P et al. (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. New Engl J Med 338:557–563CrossRefPubMed McConnell JD, Bruskewitz R, Walsh P et al. (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. New Engl J Med 338:557–563CrossRefPubMed
20.
Zurück zum Zitat Metzker H, Kieser M, Hölscher U (1996) Wirksamkeit eines Sabal-Urtica-Kombinationspräparats bei der Behandlung der benignen Prostatahyperplasie (BPH). Urologe B 36:292–300CrossRef Metzker H, Kieser M, Hölscher U (1996) Wirksamkeit eines Sabal-Urtica-Kombinationspräparats bei der Behandlung der benignen Prostatahyperplasie (BPH). Urologe B 36:292–300CrossRef
21.
Zurück zum Zitat Nickel JC (1998) Placebo therapy of benign prostatic hyperplasia: a 25-month study. Canadian PROSPECT Study Group. Br J Urol 81:383–387PubMed Nickel JC (1998) Placebo therapy of benign prostatic hyperplasia: a 25-month study. Canadian PROSPECT Study Group. Br J Urol 81:383–387PubMed
22.
Zurück zum Zitat Roehrborn CG, Abbou CC, Akaza H et al. (2001) Clinical research criteria for studies of: lower urinary tract symptoms (LUTS), enlarged prostate gland (EPG) bladder outlet obstruction (BOO) and benign prostatic hyperplasia (BPH). In: Chatelain C et al. (eds) Benign prostatic hyperplasia. 5th International Consultation on Benign Prostatic Hyperplasia (BPH), 25–28 June 2000, Paris. Health Publication, Plymouth, pp 317–395 Roehrborn CG, Abbou CC, Akaza H et al. (2001) Clinical research criteria for studies of: lower urinary tract symptoms (LUTS), enlarged prostate gland (EPG) bladder outlet obstruction (BOO) and benign prostatic hyperplasia (BPH). In: Chatelain C et al. (eds) Benign prostatic hyperplasia. 5th International Consultation on Benign Prostatic Hyperplasia (BPH), 25–28 June 2000, Paris. Health Publication, Plymouth, pp 317–395
23.
Zurück zum Zitat Roehrborn CG, Abbou CC, Allona-Almagro A et al. (1998) BPH: clinical research criteria. In: Denis L et al. (eds) Fourth International Consultation on BPH. Paris, 2–5 July 1997, Proceedings. Scientific Communication International, Channel Islands, pp 439–491 Roehrborn CG, Abbou CC, Allona-Almagro A et al. (1998) BPH: clinical research criteria. In: Denis L et al. (eds) Fourth International Consultation on BPH. Paris, 2–5 July 1997, Proceedings. Scientific Communication International, Channel Islands, pp 439–491
24.
Zurück zum Zitat Sökeland J (2000) Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome. Br J Urol 86:439–442 Sökeland J (2000) Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome. Br J Urol 86:439–442
25.
Zurück zum Zitat Sökeland J, Albrecht J (1997) Kombination aus Sabal- und Urticaextrakt vs. Finasterid bei BPH (Stad. I bis II nach Alken). Vergleich der therapeutischen Wirksamkeit in einer einjährigen Doppelblindstudie. Urologe A 36:327–333CrossRefPubMed Sökeland J, Albrecht J (1997) Kombination aus Sabal- und Urticaextrakt vs. Finasterid bei BPH (Stad. I bis II nach Alken). Vergleich der therapeutischen Wirksamkeit in einer einjährigen Doppelblindstudie. Urologe A 36:327–333CrossRefPubMed
26.
Zurück zum Zitat Treagust J, Morkane T, Speakman M (2001) Estimating a population’s needs for the treatment of lower urinary tract symptoms in men: what is the extent of unmet need? J Public Health Med 23:141–147CrossRefPubMed Treagust J, Morkane T, Speakman M (2001) Estimating a population’s needs for the treatment of lower urinary tract symptoms in men: what is the extent of unmet need? J Public Health Med 23:141–147CrossRefPubMed
27.
Zurück zum Zitat Vontobel HP, Herzog R, Rutishauser G, Kres H (1985) Ergebnisse einer Doppelblindstudie über die Wirksamkeit von ERU-Kapseln in der konservativen Behandlung der benignen Prostatahyperplasie. Urologe A 24:49–51 Vontobel HP, Herzog R, Rutishauser G, Kres H (1985) Ergebnisse einer Doppelblindstudie über die Wirksamkeit von ERU-Kapseln in der konservativen Behandlung der benignen Prostatahyperplasie. Urologe A 24:49–51
28.
Zurück zum Zitat Wilt TJ, Ishani A, Rutks I, MacDonald R (2000) Phytotherapy for benign prostatic hyperplasia. Public Health Nutr 3:459–472PubMed Wilt TJ, Ishani A, Rutks I, MacDonald R (2000) Phytotherapy for benign prostatic hyperplasia. Public Health Nutr 3:459–472PubMed
29.
Zurück zum Zitat Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C (1998) Saw palmetto extracts for treatment of benign prostatic hyperplasia. A systematic review. JAMA 280:1604–1609CrossRefPubMed Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C (1998) Saw palmetto extracts for treatment of benign prostatic hyperplasia. A systematic review. JAMA 280:1604–1609CrossRefPubMed
Metadaten
Titel
Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms—a placebo-controlled, double-blind, multicenter trial
verfasst von
N. Lopatkin
A. Sivkov
C. Walther
S. Schläfke
A. Medvedev
J. Avdeichuk
G. Golubev
K. Melnik
N. Elenberger
U. Engelmann
Publikationsdatum
01.07.2005
Verlag
Springer-Verlag
Erschienen in
World Journal of Urology / Ausgabe 2/2005
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-005-0501-9

Weitere Artikel der Ausgabe 2/2005

World Journal of Urology 2/2005 Zur Ausgabe

Invited Editorial

Ejaculatory disorders

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.